Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials

RELATIVITY-1093 Study Information

Learn more about the RELATIVITY-1093 / CA224-1093 study

BMS Recruiting Study icon

Recruiting

RELATIVITY-1093 is a phase 3, randomized, open-label study of Nivolumab + Relatlimab fixed-dosed combination with chemotherapy versus Pembrolizumab with chemotherapy as first-line treatment for participants with non-squamous, stage IV or recurrent non-small cell lung cancer with tumor cell PD-L1 expression ≥ 1%.

Summary

  • Phase 3
  • All gender icon
  • 18+
    Age Range
  • 133
    Locations

Nearest Recruiting Site

Download and print the details of this study to bring to your doctor.

Download Study Information

Key Eligibility Criteria

decorative

Patients who are 18 years or older.

decorative

Diagnosed with non-squamous stage IV or recurrent NSCLC.

decorative

Has not received any prior systemic anti-cancer therapy for advanced disease.

decorative

Confirmed not to have EGFR, ALK, or ROS-1 mutations.

decorative

PD-L1 Expression ≥1% after testing by central laboratory.

decorative

ECOG Performance Status of less than or equal to 1 at both screening and randomization.

decorative

Life expectancy of at least 3 months.

*There are other requirements for taking part in this clinical trial which the study staff can explain to you. Talk to your doctor or reach out to your nearest study site using the location finder.

Resources are also available for your healthcare team at Rela1093studyHCP.com >

Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
Check Your Eligibility
Answer some questions about Your health to see if you may match to this trial
Match to a Trial
If you are a match, click on the study to see the list of study site locations
Select a Study Site Location
Select a study site location that is convenient for you
Register
Provide your contact details for the study site to connect with you.

All BMS Non-Small Cell Lung Cancer Trials

BMS-NSCLCTrials.com
Back to Top Back to Top

Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you